These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 19966139)
21. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. Liu DQ; Chen TK; McGuire MA; Kord AS J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156 [TBL] [Abstract][Full Text] [Related]
22. Strategies for the investigation and control of process-related impurities in drug substances. Argentine MD; Owens PK; Olsen BA Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658 [TBL] [Abstract][Full Text] [Related]
23. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities. Brusick DJ Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870 [TBL] [Abstract][Full Text] [Related]
24. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities. Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841 [TBL] [Abstract][Full Text] [Related]
25. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Gocke E; Bürgin H; Müller L; Pfister T Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796 [TBL] [Abstract][Full Text] [Related]
26. Impurities in drug substances and drug products: new approaches to quantification and qualification. Berridge JC J Pharm Biomed Anal; 1995 Dec; 14(1-2):7-12. PubMed ID: 8833961 [TBL] [Abstract][Full Text] [Related]
27. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E; Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066 [TBL] [Abstract][Full Text] [Related]
28. Eliminating pharmaceutical impurities: Recent advances in detection techniques. Liu DQ; Sun M; Wu L Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235 [TBL] [Abstract][Full Text] [Related]
29. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Bolt HM; Foth H; Hengstler JG; Degen GH Toxicol Lett; 2004 Jun; 151(1):29-41. PubMed ID: 15177638 [TBL] [Abstract][Full Text] [Related]
30. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate. Müller L; Gocke E Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798 [TBL] [Abstract][Full Text] [Related]
31. The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product. Dow LK; Hansen MM; Pack BW; Page TJ; Baertschi SW J Pharm Sci; 2013 May; 102(5):1404-18. PubMed ID: 23436613 [TBL] [Abstract][Full Text] [Related]
32. The Threshold of Toxicological Concern (TTC) in risk assessment. Munro IC; Renwick AG; Danielewska-Nikiel B Toxicol Lett; 2008 Aug; 180(2):151-6. PubMed ID: 18573621 [TBL] [Abstract][Full Text] [Related]
33. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds. Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283 [TBL] [Abstract][Full Text] [Related]
34. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251 [TBL] [Abstract][Full Text] [Related]
35. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. Elder DP; Snodin D; Teasdale A J Pharm Biomed Anal; 2011 Apr; 54(5):900-10. PubMed ID: 21145684 [TBL] [Abstract][Full Text] [Related]
36. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review. Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762 [TBL] [Abstract][Full Text] [Related]
37. Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals. Corrigan DK; Whitcombe MJ; McCrossen S; Piletsky S J Pharm Pharmacol; 2009 Apr; 61(4):533-7. PubMed ID: 19298702 [TBL] [Abstract][Full Text] [Related]
38. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU. Gocke E; Ballantyne M; Whitwell J; Müller L Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969 [TBL] [Abstract][Full Text] [Related]
39. Risk assessment of dietary exposures to compounds that are genotoxic and carcinogenic--an overview. Dybing E; O'Brien J; Renwick AG; Sanner T Toxicol Lett; 2008 Aug; 180(2):110-7. PubMed ID: 18584977 [TBL] [Abstract][Full Text] [Related]
40. Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities. Fioravanzo E; Bassan A; Pavan M; Mostrag-Szlichtyng A; Worth AP SAR QSAR Environ Res; 2012; 23(3-4):257-77. PubMed ID: 22369620 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]